The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.
All content for Pharm5 is the property of Elizabeth B. Hearn, PharmD, BCACP and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.
Ivermectin vs. COVID-19, Cabenuva vs. Biktarvy, and more!
Pharm5
4 minutes 30 seconds
2 years ago
Ivermectin vs. COVID-19, Cabenuva vs. Biktarvy, and more!
This week on Pharm5:
Ivermectin fails against COVID-19
Cabenuva noninferior to Biktarvy
Syfovre for geographic atrophy
Aspirin for pre-eclampsia prevention
TRUNCATE-TB results could shorten TB treatment
Connect with us!
Listen to our podcast: Pharm5
Follow us on Twitter: @LizHearnPharmD
References:
Naggie S, Boulware DR, Lindsell CJ, et al. Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with covid-19. JAMA. February 2023. doi:10.1001/jama.2023.1650.
Efficacy: Cabenuva (cabotegravir; Rilpivirine). Efficacy: Every 2 Month | CABENUVA Official HCP Website. http://bit.ly/3kpnkdU. Accessed February 23, 2023.
VIIV healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, Rilpivirine) is as effective as daily oral biktarvy (BIC/FTC/TAF) for the treatment of HIV-1. ViiV Healthcare. http://bit.ly/3m14uKy. Accessed February 23, 2023.
Low-dose aspirin use for the prevention of preeclampsia and related morbidity and mortality. ACOG. http://bit.ly/3kuekE7. Accessed February 23, 2023.
Mendoza M, Bonacina E, Garcia-Manau P. Aspirin discontinuation at 24 to 28 weeks’ gestation in pregnancies a high risk of preterm preeclampsia:
a randomized clinical trial. JAMA. February 2023. doi: 10.1001/jama.2023.0691.
FDA Oks first drug for geographic atrophy, a major cause of adult blindness. FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness. http://bit.ly/3ZgFwoE. Published February 17, 2023. Accessed February 22, 2023.
Paton NI, Cousins C, Suresh C, et al. Treatment strategy for rifampin-susceptible tuberculosis. New England Journal of Medicine. 2023. doi:10.1056/nejmoa2212537
Treatment for TB disease. Centers for Disease Control and Prevention. http://bit.ly/3Y5HxTW. Published March 7, 2022. Accessed February 23, 2023.
Pharm5
The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.
